Back to Search
TIMOTHY FRANCIS CLOUGHESY MD
MD
Neurology Physician
NPI: 1154356053IndividualAccepts Medicare
Specialties, Licenses & Credentials
Neurology PhysicianPrimary
Psychiatry & Neurology — Neurology
Code: 2084N0400X
G63435(CA)
Hematology & Oncology Physician
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
G63435(CA)
Education
TULANE UNIVERSITY SCHOOL OF MEDICINE
Class of 1987
Research & Publications (20)
Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma.
PMID 18215105·PLoS Med·2008
3-trial
Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
PMID 16877733·J Clin Oncol·2006
3-trial
Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
PMID 16170172·J Clin Oncol·2005
3-trial
Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.
PMID 12712460·Cancer·2003
8-other
Irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.
PMID 11943904·Am J Clin Oncol·2002
3-trial
Stem cell associated gene expression in glioblastoma multiforme: relationship to survival and the subventricular zone.
PMID 19655089·J Neurooncol·2010
8-other
Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.
PMID 19562255·J Neurooncol·2010
3-trial
The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis.
PMID 19625624·Proc Natl Acad Sci U S A·2009
7-preclinical
Neurosphere formation is an independent predictor of clinical outcome in malignant glioma.
PMID 19353526·Stem Cells·2009
7-preclinical
Targeted therapy for malignant glioma patients: lessons learned and the road ahead.
PMID 19560740·Neurotherapeutics·2009
6-review
Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis.
PMID 19573811·Cancer Cell·2009
7-preclinical
A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas.
PMID 18850068·J Neurooncol·2009
3-trial
A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05).
PMID 18797818·J Neurooncol·2009
3-trial
The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity.
PMID 18812520·Neuro Oncol·2009
8-other
Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience.
PMID 19349600·Neurology·2009
8-other
18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience.
PMID 18511228·Eur J Radiol·2009
8-other
The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers.
PMID 19478061·Proc Natl Acad Sci U S A·2009
8-other
Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment.
PMID 19561256·Radiology·2009
2-rct
Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
PMID 19293394·Neuro Oncol·2009
3-trial
Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors.
PMID 19468690·J Neurooncol·2009
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 300 MEDICAL PLAZA SUITE B-200
LOS ANGELES, CA 90095 - Phone
- (310) 794-1195
Quick Facts
- NPI
- 1154356053
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 2
- Years in Practice
- 39
- Publications
- 20
Are you this provider?
Claim Your Profile